SCHEMBL3106830

SCHEMBL3106830

COCCNC(=O)c1ccc(-n2cc(C(=O)NC3CC3)nn2)c(OCCCCCCF)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.45
CYP2C9 P11712 1/20 0.45
TP53 P04637 1/20 0.41
ACKR3 P25106 1/20 0.41
SMPD1 P17405 1/20 0.40
CNR2 P34972 2/20 0.39
RIPK2 O43353 1/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112178 0.92 ACKR3 (0.41) MAPK14ACKR3SMPD1CNR2HPGD
SCHEMBL3107180 0.92 ACKR3 (0.41) MAPK14ACKR3SMPD1CNR2HPGD
SCHEMBL3110327 0.92 ACKR3 (0.42) MAPK14ACKR3SMPD1CNR2HPGD
SCHEMBL5246436 0.90 ACKR3 (0.44) MAPK14ACKR3CNR2
SCHEMBL3103926 0.90 ACKR3 (0.44) ACKR3CNR2
SCHEMBL5245285 0.87 BRD4 (0.43) ACKR3CNR2
SCHEMBL5244865 0.87 ACKR3 (0.43) ACKR3CNR2
SCHEMBL3115558 0.87 TP53 (0.41) CYP2C9TP53SMPD1CNR2HTT
SCHEMBL3110965 0.86 ACKR3 (0.43) MAPK14ACKR3CNR2HPGD
SCHEMBL3113338 0.85 SMPD1 (0.43) MAPK14ACKR3SMPD1CNR2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 MAPK14 1769/4885CYP2C9 494/4885TP53 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.